Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan

Chugai Pharmaceutical said on July 4 that it has launched Hemlibra (emicizumab) in Taiwan for the routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors. The drug has been previously available...read more